Cytotoxicity and tolerance to DNA adducts of alicyclic mixed amine platinum(II) homologs in tumor models sensitive and resistant to cisplatin or tetraplatin

Oncology Reports

Volumn 5, Issue 5, 1998, Pages 1281-1287

  Yoshida, Motofumi ^a   Khokhar, Abdul R ^a   Siddik, Zahid H ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Alicyclic mixed amine complex; DNA damage tolerance; Drug resistance; Structure activity relationship

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALICYCLIC AMINE; CISPLATIN; CYCLOBUTANE DERIVATIVE; CYCLOHEPTANE DERIVATIVE; CYCLOHEXANE DERIVATIVE; CYCLOPENTANE DERIVATIVE; CYCLOPROPANE DERIVATIVE; DNA; OCTYLAMINE; PLATINUM DERIVATIVE; TETRAPLATIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TOLERANCE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

EID: 0031829097     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.5.1281     Document Type: Article

References (31)

1. Krakoff IH: The development of more effective platinum therapy. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Nicolini M (ed). Martinus Nijhoff, Boston, pp351-354, 1988.
2. Harrap KR: Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 12 (Suppl. A): 21-33, 1985.
3. Gore M, Fryatt I, Wiltshaw E, Dawson T, Robinson B and Calvert A: Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer 60: 767-769, 1989.
4. Andrews PA and Howell SB: Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35-43, 1990.
5. Johnson SW, Laub PB, Beesley JS, Ozols RF and Hamilton TC: Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 57: 850-856, 1997.
6. Kelland LR: New platinum antitumor complexes. Grit Rev Oncol Hematol 15: 191-219, 1993.
7. Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P and Harrap KR: Ammine/amine platinum(IV) dicarfaoxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 52: 822-828, 1992.
8. Harrap KR, Kelland LR, Jones M, Goddard PM, Orr RM, Morgan SE, Murrer BA, Abrams MJ and Giandomenico CM: Platinum coordination complexes which circumvent cisplatin resistance. Adv Enzyme Regul 31: 31-43, 1991.
9. McKeage MJ, Raynaud F, Ward J, Berry C, O'Dell D, Kelland LR, Murrer B, Santabarabara P, Harrap KR and Judson : Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 15: 2691-2700, 1997.
10. Pendyala L, Arakali AV, Sansone P, Cowens JW and Creaven PJ: DNA binding of iproplatin and its divalent metabolite cis-dichloro-bis-isopropylamine platinum(II). Cancer Chemother Pharmacol 27: 248-250, 1990.
11. Kido Y, Khokhar AR and Siddik ZH: Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cells. Anti-Cancer Drugs 4: 251-258, 1993.
12. Kido Y, Khokhar AR, Al-Baker S and Siddik ZH: Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum(IV) complexes mediated by axial and equatorial ligands. Cancer Res 53: 4567-4572, 1993.
13. Kido Y, Khokhar AR and Siddik ZH: Glutathione-mediated modulation of tetraplatin activity against sensitive and resistant tumor cells. Biochem Pharmacol 47: 1635-1642, 1994.
14. Yoshida M, Khokhar AR and Siddik ZH: Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant cell lines. Cancer Res 54: 3468-3473, 1994.
15. Poon GK, Raynaud FI, Mistry P, Odell DE, Kelland LR, Harrap KR, Barnard CF and Murrer BA: Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry. J Chromatgr 712(A): 61-66, 1995.
16. Vollano JF, Al-Baker S, Dabrowiak JC and Schurig JE: Comparative antitumor studies on platinum(II) and platinum(IV) complexes containing 1,2-diaminocyclohexane. J Med Chem 30: 716-719, 1987.
17. Khokhar AR, Deng Y, Al-Baker S, Yoshida M and Siddik ZH: Synthesis and antitumor activity of ammine/amine platinum(II) and (IV) complexes. J Inorg Biochem 51: 677-687, 1993.
18. Eastman A and Illenye S: Murine leukemia L1210 cell lines with different patterns of resistance to platinum coordination complexes. Cancer Treat Rep 68: 1189-1190, 1984.
19. Richon VM, Schultz N and Eastman A: Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res 47: 2056-2061, 1987.
20. Eastman A: Glutathione-mediated activation of anticancer platinum(IV) complexes. Biochem Pharmacol 36: 4177-4178, 1987.
21. Perez KP, O'Dwyer PJ, Handel LM, Ozols RF and Hamilton TC: Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines. Int J Cancer 48: 265-269, 1991.
22. Tanaka Y, Eda H, Tanaka T, Udagawa T, Ishikawa T, Horii I, Ishitsuka H, Kataoka T and Taguchi T: Experimental cancer cachexia induced by transplantable Colon 26 adenocarcinoma in mice. Cancer Res 50: 2290-2295, 1990.
23. Teicher BA and Rose CM: Perfluorochemical emulsions can increase tumor radiosensitivity. Science 223: 934-936, 1984.
24. Carmichael J, deGraff W, Gazdar A, Minna J and Mitchell J: Evaluation of a tetrazolium-based semi-automatic colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987.
25. Siddik ZH, Mims B, Lozano G and Thai G: Independent pathways of p53 induction by cisplatm and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res 58: 698-703, 1998.
26. Farrell N, Qu Y, Feng L and van Hauten B: Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequence specificity of bis(platinum) complexes containing monodentate or bidentate coordination spheres with their monomeric analogues. Biochemistry 29: 9522-9531, 1990.
27. Braddock PD, Connors TA, Jones M, Khokhar AR, Melzack DH and Tobe ML: Structure and activity relationships of platinum complexes with anti-tumor activity. Chem-Biol Interact 11: 145-161, 1975.
28. Bradner WT, Rose WC and Huttalen JB: Antitumor activity of platinum analogs. In: Cisplatin: Current Status and New Developments. Prestayko AW, Crooke ST and Carter SK (eds). Academic Press, New York, pp171-182, 1980.
29. Hirano T, Inagaki K, Alink M, Nakahara H and Kidani Y: Cytotoxicity of asymmetric platinum complexes against L-1210 cells: effect of bulky substituents. Chem Pharm Bull 38: 2850-2852, 1990.
30. Gibbons GR, Wyrick S and Chancy SG: Rapid reduction of tetrachloro(D,L-trans) 1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium. Cancer Res 49: 1402-1407, 1989.
31. Giandomenico CM, Abrams MJ, Murrer MJ, Vollano JF, Barnard CFJ, Harrap KR, Goddard PM, Kelland LR and Morgan SE: Synthesis and reactions of a new class of orally active Pt(IV) antitumor complexes. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Howell SB (ed). Plenum Press, New York, London pp93-100, 1991.